-
Mashup Score: 0
Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.
Source: www.biospace.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 14Opinion: ALS Is Not a Singular Disease. Stop Treating It Like One - 2 month(s) ago
Imagine testing a really good drug for HER2+ breast cancer in someone with liver cancer. Would it be any surprise when that drug fails?
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 3Merck’s Keytruda Continues NSCLC Losing Streak with Phase III Flop - 2 month(s) ago
Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System - 2 month(s) ago
Cleerly ® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System.
Source: www.biospace.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Pilot Study Shows Better eConsents Create Better Human Experiences - 2 month(s) ago
Electronic consent can personalize the patient experience in clinical trials and even improve retention. At Medable, where I am CSO, we’re committed to driving the adoption of this transformative technology.
Source: www.biospace.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 25
On Friday, Alvotech and Teva Pharmaceuticals finally secured the FDA’s greenlight for their Humira biosimilar Simlandi, which now has the regulator’s interchangeability designation.
Source: www.biospace.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12
On Friday, Alvotech and Teva Pharmaceuticals finally secured the FDA’s greenlight for their Humira biosimilar Simlandi, which now has the regulator’s interchangeability designation.
Source: www.biospace.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4Turning to Patients to Help Drive Rare Disease Drug Development - 2 month(s) ago
Patient advocacy groups aided in the development of the very first marketed drugs for certain rare diseases, including progeria and Friedreich’s ataxia.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 9Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial - 3 month(s) ago
In a Phase II study, Sanofi and Denali’s RIPK1 inhibitor SAR443820/DNL788 failed to meet the primary endpoint of improved functional performance in amyotrophic lateral sclerosis patients.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 9FDA Approves First One-time Cell Therapy for a Solid Tumor - 3 month(s) ago
On Friday, the regulator greenlit Iovance’s lifileucel to treat advanced melanoma. Prior to the approval, experts told BioSpace that tumor-infiltrating lymphocytes therapies also hold the potential to treat several other solid tumors.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
funny that J/J walked away last fall from this https://t.co/14AhTB2Wtk